News Search Results
Jul 23, 2024, 17:40 ET Industrial Turbocharger Market size is set to grow by USD 773.4 million from 2024-2028, Stringent emission regulations boost the market, Technavio
global Artificial Blood Substitutes Market is expanding due to rising healthcare needs and technological advancements in synthetic biology, aiming to address blood shortages. In contrast, the
More news about: Technavio
Jul 19, 2024, 10:00 ET Antheia Announces New Funding to Support Domestic Production of Critical Pharmaceutical Ingredients
world-class founders, ideas, and capital to generate exceptional financial and social returns. "The U.S. is a leader in biomanufacturing, synthetic biology, and computational biology, but there is more we must do to scale these advanced technologies to solve global problems like essential medicine
More news about: Antheia
Jul 18, 2024, 10:15 ET Biologics Market: Surging with 10.40% CAGR Amid Fewer Chronic Cases | SkyQuest Technology
therapies. Related Reports: Synthetic Biology Market Biologics Safety Testing
More news about: SkyQuest Technology
Jul 18, 2024, 08:30 ET Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals
in animal health, AbCellera, a global technology company specializing in antibody discovery, Twist Bioscience, a leading and rapidly growing synthetic biology and genomics company, and WuXi Biologics, a global company with leading biologics technology platforms. Invetx is headquartered in
More news about: Novo Holdings
Jul 17, 2024, 06:00 ET PhaBuilder collaborates with Solenis and Hengxin
implements the synthetic biology innovation path of "PHAmily-PHAbrary-PHAdustry-PHA Life". In the future, PhaBuilder will provide sustainable solutions based on green bio-based materials to customers worldwide by positioning itself as "a global leader in synthetic biology and bio-manufacturing".
More news about: Beijing Phabuilder Biotechnology Co., Ltd.
Jul 16, 2024, 13:00 ET John Nicols Appointed Strategic Advisor to bitBiome
traditional chemistry. He is the former president and CEO of Codexis, where he led the growth and transformation of Codexis into one of the leading synthetic biology companies. From 2013 to 2022, Nicols quintupled Codexis' sales to exceed $100 million, commercializing dozens of
More news about: bitBiome
Jul 16, 2024, 07:01 ET Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Jul 15, 2024, 09:15 ET First Type 1 Diabetes Patient Enrolled in Rise Therapeutics' Latest Clinical Trial
emerging, privately held biotechnology company located in Rockville, Maryland, which leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal
More news about: Rise Therapeutics
Jul 15, 2024, 01:47 ET CPHI & PMEC Shenzhen 2024: Fostering New Opportunities in Asia and China's Greater Bay Area
sessions. These sessions will delve into critical topics such as pharma manufacturing 4.0, global API trading trends, biopharmaceutical R&D, synthetic biology innovation, as well as offering unparalleled insight into regulatory updates and the market trends shaping the pharmaceutical landscape.
More news about: CPHI & PMEC Shenzhen 2024
Jul 05, 2024, 04:07 ET Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar), which is a synthetic biology-driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their core pipeline
More news about: Biostar Pharma, Inc.
Jul 02, 2024, 09:00 ET Debut Expands Partnership with L'Oréal to Develop and Scale Biotech Ingredients Crucial for Sustainable Beauty
climate change, worsening pollution and the unabating demand on natural resources, there is urgent need for sustainable ingredient sourcing. Synthetic biology, which Boston Consulting Group described as "the manufacturing paradigm of the future", can deliver the innovation needed to create bio-identical,
More news about: Debut
Jun 25, 2024, 10:00 ET Daicel Arbor Biosciences launches new myTXTL® kits to accelerate protein expression
a simple library screen, CRISPR-Cas activity assays, or test gene circuits, the Pro Kit can serve multiple purposes in protein expression and synthetic biology. In addition, the
More news about: Daicel Arbor Biosciences
Jun 18, 2024, 19:00 ET Protein Engineering Market size is set to grow by USD 3.60 billion from 2024-2028, demand for improved food and industrial products boost the market, Technavio
Monoclonal antibodies, a protein type, are a significant component of protein-based therapies, which contribute to improved patient outcomes. Synthetic biology and non-protein drugs also hold potential in this market. Precision medicine and the immune system are integral areas of application for these
More news about: Technavio
Jun 18, 2024, 17:57 ET GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market
June 18, 2024 /PRNewswire/ -- GenScript Biotech Corporation, renowned for its relentless innovation in synthetic biology and industry-leading gene synthesis services, is excited to announce the launch of its newest offering, GenScript FLASH Gene service, the ultra-fast
More news about: GenScript Biotech Corporation
Jun 18, 2024, 15:17 ET New England Biolabs® and Inorevia to partner on novel solutions for the preparation of challenging samples for next generation sequencing
NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key
More news about: New England Biolabs, Inc.
Jun 18, 2024, 03:47 ET VTT begins search for innovation partner for scaling up Finland's next quantum computer towards 300 qubits
of the development project. Accelerating the application of quantum computing It is predicted that materials research, synthetic biology research, the pharmaceutical industry, and the financial sector will be among the first industries to benefit from quantum computing. Quantum
More news about: VTT Info
Jun 12, 2024, 22:00 ET NSG BioLabs and Eppendorf Group Sign Partnership to Support Biotech Companies in Singapore
biomedical, agrifood, and industrial biotechnology sectors, working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, synthetic biology, and other impactful areas. With the largest co-working biotech laboratory and office footprint in Singapore,
More news about: NSG BioLabs
Jun 03, 2024, 08:00 ET Matterworks Launches PyxisTM - First AI-Powered, Turn-Key Platform for Identification and Absolute Quantitation from Mass Spectrometry Data
biological insight and discovery potential from routine molecular data." "We've worked extensively with collaborators in the drug development, synthetic biology, and microbiome markets," added Jennifer M. Campbell, CSO at Matterworks. "Understanding their challenges has enabled
More news about: Matterworks
May 23, 2024, 05:36 ET Oligonucleotide Synthesis Market size is set to grow by USD 3.37 billion from 2024-2028, Growing shift toward RNA-based therapeutics boost the market, Technavio
for genome projects, therapeutic drugs, and molecular testing in clinical studies. Key technologies include CRISPR, vector technologies, and synthetic biology. Market Challenges Oligonucleotide synthesis is a critical process in the production of therapeutics and
More news about: Technavio
May 21, 2024, 10:07 ET Prof. Jay Shendure Joins Somite Therapeutics as Scientific Co-founder
Institute, a Professor of Genome Sciences at the University of Washington, and Scientific Director of the Seattle Hub for Synthetic Biology (Allen-CZI-UW), the Allen Discovery Center for Cell Lineage Tracing, and the Brotman Baty Institute for Precision Medicine. His lab is known for
More news about: Somite Therapeutics
May 15, 2024, 09:30 ET Fermbox Bio Introduces EN3ZYME: A Global Solution Transforming Agricultural Waste into Renewable Biofuels and Sustainable Synbio Products
BANGALORE, India, May 15, 2024 /PRNewswire/ -- Fermbox Bio, a synthetic biology research and manufacturing company, announces the launch of EN3ZYME, a cutting-edge enzyme cocktail designed to enhance both the efficiency and
More news about: Fermbox Bio
May 15, 2024, 05:07 ET Fermbox Bio launches its first product in its Synbio product pipeline: A cellulosic enzyme cocktail to transform agricultural waste into 2G ethanol
May 15, 2024 /PRNewswire/ -- Fermbox Bio, a synthetic biology research and manufacturing company,
More news about: Fermbox Bio
May 15, 2024, 03:55 ET VTT Info: A new revolutionary method accelerates the development of sustainable biomaterials from years to minutes
researchers of VTT Technical Research Centre of Finland, introduces a transformative approach that integrates synthetic biology with advanced machine learning and computational techniques to significantly accelerate the development of new biomaterials. This method reduces
More news about: VTT Info
May 14, 2024, 18:00 ET Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan
into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.
More news about: Ginkgo Bioworks
May 13, 2024, 16:05 ET Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE
and other expectations, and to identify and realize additional business opportunities, (v) the risk of downturns in demand for products using synthetic biology, (vi) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vii) changes to the biosecurity industry,
More news about: Ginkgo Bioworks